📄 Direct examination of Gregory Matheson (part 3) — Tuesday, May 2, 1995
Address:
C:\DEPT103\CRIMINAL\1995\MAY\2\DIRECT-EXAMINATION-OF-GREGORY-.DOC
TRIAL
▲ Day 65 of 167

Direct examination of Gregory Matheson (part 3)

Witness: Gregory Matheson
Examiner: Hank Goldberg
Called by: Prosecution • Date: Tuesday, May 2, 1995 • Utterances: 471
LAPD senior criminalist Gregory Matheson continued his direct examination under Hank Goldberg, walking the jury through the electrophoresis technique used to identify genetic markers in blood evidence and explaining the serology results chart (People's 202) summarizing his testing of key evidence items from June and September 1994. A notable moment arose when Goldberg addressed an apparent inconsistency: at the preliminary hearing Matheson had testified that he performed the electrophoresis tests himself, without disclosing that colleague Corinne Yamauchi had done the physical gel loading under his supervision — a distinction the prosecution preemptively clarified using Matheson's own contemporaneous analyzed evidence report.
1 THE COURT:

All right. Thank you, ladies and gentlemen. The record should reflect that we have now been rejoined by all the members of our jury panel. Mr. Gregory Matheson is again on the witness stand undergoing direct examination by Mr. Goldberg. And Mr. Goldberg, you may continue.

2 MR. GOLDBERG:

Thank you.

3 (Discussion held off the record between the Deputy District Attorneys.)
4 THE COURT:

Mr. Goldberg.

5 MR. GOLDBERG:

Thank you, your Honor.

6 MR. GOLDBERG:

Mr. Matheson, yesterday you were testifying about using a process called electrophoresis?

7 MR. MATHESON:

That's correct.

8 MR. GOLDBERG:

And can you tell was that is?

9 MR. MATHESON:

Electrophoresis is a technique that is used to identify the different enzyme types, these polymorphic enzymes that we were talking about before.

10 MR. GOLDBERG:

So is electrophoresis used on ABO or just the enzymes?

11 MR. MATHESON:

Well, in the case of the type of testing we are talking about here it is not used in the ABO, it is used in enzymes, and it is used in other purposes, too.

12 MR. GOLDBERG:

And can you give us an explanation of how the electrophoresis technique works?

13 MR. MATHESON:

Well, like in the ABO system where you have different types that can be identified in these enzymes, they also exist in different types. An example being a PGM that I mentioned earlier, in its simple form it is a type 1 a type 2-1 and a 2. Each of these types differ slightly in their structure, in their charge. That is one of the ways we use to tell them apart. The electrophoretic technique involves taking a glass plate that is approximately about eight inches square, pouring what is called an agarose gel on it, which is kind of like a Jell-O like substance on the top of it, placing the samples on--you take small portions of the blood or the cloth, absorb it onto threads, insert it down into the gel all in a line.

this then is placed on that cooling bath and electricity is allowed to run through it from one side to the other in one direction and this basically kind of pushes the enzymes along and they travel at different rates based on this charge that is on them, the slight differences. After a predetermined amount of time, you stop that electrical process and put chemicals on it over the top that work with the enzyme so you can see where the bands lined up. In most of the systems you identify the type by the quantity and location of these bands on the gel and in some systems you do it as far as location and quantity along with the intensity or the darkness or brightness of each of the individual bands.

14 MR. GOLDBERG:

So after running this electrophoresis gel, you get some kind of a banding pattern?

15 MR. MATHESON:

That's correct.

16 MR. GOLDBERG:

And then what do you do with that banding pattern after it appears?

17 MR. MATHESON:

Well, each different type of an enzyme will give a unique banding pattern so you are then able to interpret it. You don't just do it from memory, though. On each of those gels or each of the plates that I was talking about, which with the system that we have set up we can run up to twelve samples on it, out of those twelve samples three or four of them may be a control or known sample of all the different types that are present in the system. So you would have a situation where would you have a sample, a control, a couple samples and a control. That way you can make direct comparisons between your unknown sample and your known types and make the call and determine what type it is.

18 MR. GOLDBERG:

Your Honor, at this time I would like to mark as People's next in order, it is 215 for identification, another board entitled "Evidence testing demonstration."

19 (Discussion held off the record between the Deputy District Attorneys.)
20 THE COURT:

All right. 215.

21 (Peo's 215 for id = posterboard)
22 THE COURT:

Can we put that up just a little bit higher?

23 (Brief pause.)
24 THE COURT:

1492, can you see that? Up a little.

25 JUROR 1492:

That's fine.

26 THE COURT:

Thank you. Mr. Goldberg.

27 MR. GOLDBERG:

Thank you.

28 MR. GOLDBERG:

Sir, directing your attention to this exhibit 215 for identification, the first photograph, photograph no. 1, "Door to serology." May I have that on the elmo? What does that photograph depict?

29 MR. MATHESON:

It depicts the door into the serology lab from that hallway from the chart that kind of goes around in a square around the laboratory itself. It is always--when you are talking about windows before, although there are no windows to the outside, each of the laboratories has a couple of windows that look from the lab itself into the hallway.

30 MR. GOLDBERG:

So from the hallway you can see what is going on inside the laboratory?

31 MR. MATHESON:

In most areas; some areas you can't see.

32 MR. GOLDBERG:

Now, directing your attention to cell no. 2 on this demonstration exhibit, what does that show?

33 MR. MATHESON:

That is a photograph that is taken if you were to walk just inside the door shown in cell 1 and turn to the left. It looks down through the serology laboratory. What you see on the left is a personal work bench area or one of the areas of one of our criminalists. To the right you can just barely make out a little bit of a layout table, and then farther back on the right is one of our group or analytical areas.

34 MR. GOLDBERG:

And can you see where the electrophoresis machines are kept in this particular photograph?

35 MR. MATHESON:

Yes, you can.

36 MR. GOLDBERG:

Where is that?

37 MR. MATHESON:

Well, by using the pointer toward the right of the photograph you can see these reddish ends, those are all the electrophoresis cooling plates or cooling tanks that I talked about earlier.

38 MR. GOLDBERG:

Now, directing your attention to cell no. 3 on this exhibit, what does this show?

39 MR. MATHESON:

Okay. As I described in the process before, in the electrophoresis, you pour a gel on a plate that is about eight inches square, something like that. That is depicted in the picture, one of those plates. The gel is on the glass part there that you can--actually can't see the gel because it is clear. Then there is a row of slits that are put in it where the samples are introduced. It is called loading the gel. Each one of these red marks that you see is indicative of either an unknown sample or a control or known sample.

40 MR. GOLDBERG:

And going through the four items here, can you tell us where the unknown samples would be, as opposed to the known sample?

41 MR. MATHESON:

Well, my practice in running a gel is I put an unknown in the first, a known sample in the second, unknown in the third and the fourth and then a known one would go in the fifth spot.

42 MR. GOLDBERG:

When you say "Unknown," you are talking about what?

43 MR. MATHESON:

Anytime I refer to an unknown sample, it is an evidence sample. We don't know the results of it at this point.

44 MR. GOLDBERG:

And the known is what?

45 MR. MATHESON:

The known is a portion of blood where we know the source of that blood and we have already characterized and known what the types of them are.

46 MR. GOLDBERG:

Is that what you used to compare the unknown against?

47 MR. MATHESON:

Yes.

48 MR. GOLDBERG:

Now, after the plate is loaded, what is done with the plate?

49 MR. MATHESON:

Okay. The plate then is laid in this--or the fourth cell here that is marked "Electrophoresis." The white part in between the two red ends is a cooling plate. There is a bath or a mechanism not too far away from here which has a refrigerant in it which lowers the temperature of the water. The water is then circulated back and forth through these plates so that the electrophoresis gel is kept at a low temperature so it is laid on top of that.

50 MR. GOLDBERG:

And finally, if we look at the fifth gel where it says "Run gel," what is this showing?

51 MR. MATHESON:

Okay. This shows a couple of different tanks side-by-side. The right one here has a gel laying on the cooling bath to actually run the electrophoresis system. There is white what are filter papers called wicks on either side of it. They are in a tank that has a buffer solution. The wicks are laid across the edges of the gel on both sides and then there is cords that go up to the power supply located toward the top of the picture and electricity is run through the buffer, through the wicks, across the gel and then back into the power supply. They have to be kept cold because most of our systems in this type run at approximately 350, 400 volts and that would--if there wasn't a cooling system, it would actually heat the gels up and dry them out and the process wouldn't work.

52 MR. GOLDBERG:

Now, if this were a real case and this evidence were to be run, what would you have to do after the item had been--the gel had been placed on the plate as depicted in cell 5?

53 MR. MATHESON:

Well, like I--

54 MR. GOLDBERG:

Is that door, the Plexiglas door closed or what?

55 MR. MATHESON:

Right. Like I mentioned, the wicks would have to be laid from the tanks on the edges of the gel. You close this lid because you don't want to come in contact with the voltage running through it, and the wires to the back of the unit are placed into the power supply which is above it.

56 MR. GOLDBERG:

Now, if we can go back to cell no. 4 for a second. Can you point out where it that is the samples are that have been loaded onto the gel in this photograph?

57 MR. MATHESON:

They are a little tough to see, but you see that the gel is being held up, the gel is on a piece of glass being held up on its side, and the reddish spots that show up about two inches or so from the bottom of the gel.

58 MR. GOLDBERG:

So are those closer to the analyst's right hand or left hand?

59 MR. MATHESON:

They are closer to his right hand.

60 MR. GOLDBERG:

And can you tell us using this photograph when the machine is hooked up and the electricity is actually running through it, can you describe for us what happens?

61 MR. MATHESON:

Well, as far as like I mentioned in the description before, the current runs through it, there is a positive side and a negative side, and it runs from the positive to--correction * the negative side and a positive side. It runs from the negative to the positive side and the enzymes that are present in there, they are such that they--they move along through the gel at a slightly different rate, depending on the structure of them, and the structure is what determines the type.

62 MR. GOLDBERG:

So which way do they move? As it is placed on the machine this way would they go from his right hand to his left hand or the other way?

63 MR. MATHESON:

Well, it depends on the system. This system here that is setting up appears to be a PGM subtype system that we use and it would be running from the right to the left.

64 MR. GOLDBERG:

And when they run from the right to the left, can you actually see some sort of a banding pattern with your naked eye after it is finished?

65 MR. MATHESON:

No, you cannot.

66 MR. GOLDBERG:

What do you have to do in order to see that?

67 MR. MATHESON:

After the run time you remove this gel from the cooling plate and you have prepared what are called development chemicals, and they are optimized for a particular enzyme system. The chemicals contain or the solution contains chemicals that react with the enzyme so that we can see them. Normally, if it is a visible thing that you can see with your eye in white light, it is a dark bluish almost black type of band formed. There is another type that react with what are called florescent chemicals and you have to look at them under ultraviolet light.

68 MR. GOLDBERG:

After the plate is run and the development chemicals are put on, is something done to preserve that plate?

69 MR. MATHESON:

Yes. The plate itself is not preserved; however, the results are photographed. They are actually photographed several times throughout the development process. It doesn't just pop up all at once. It slowly becomes visible in most of the systems and you take pictures along the way.

70 MR. GOLDBERG:

All right. And do you read your results off the plate or off the photographs?

71 MR. MATHESON:

Actually to some extent both. You read them from both.

72 MR. GOLDBERG:

How complex is this technique--how complex was this for you to learn how to do this technique?

73 MR. MATHESON:

Well, it is not a terribly easy technique, but it also isn't difficult. I was able to--I mentioned yesterday a course that I took back at the FBI academy which lasted about two weeks in duration. During that two weeks I went into it with having used this technique maybe less than half a dozen times or so just practicing in the laboratory. And within the two weeks I became fairly proficient at running samples.

74 MR. GOLDBERG:

Now--thank you. You said it was possible to calculate the frequencies of people that have different genetic markers that you have tested. Is there a rule known as the product rule that you apply in doing this?

75 MR. MATHESON:

Yes.

76 MR. GOLDBERG:

What is that?

77 MR. MATHESON:

What that is, is it allows you to determine the types of different markers you identify and it is possible, just through statistics, you know that going back to the ABO blood typing system that a certain percentage of the population is a type A, a certain percentage B and so this is also true of the different enzymes that I am talking about. So once you have identified the types, say, in two different markers, ABO blood system and maybe this PGM system that we have talked about, you can multiply together the percentages of each of the types that are present and come out with a smaller percentage of the population that has those two types together.

78 MR. GOLDBERG:

Can you give us an example of that?

79 MR. MATHESON:

Well, starting with the ABO system, about roughly half of the population is a type O or about fifty percent of the population. If it was the only test that was available to us, we can analyze a blood stain and determine that it is a type O and the best information out of that is that half the people in this room could have contributed that blood stain. Well, then we go ahead and run one of these additional genetic markers. Let's say out of that we identify a type that also exists in fifty percent of the population. Well, now we have two pieces of information. You can multiply those two together and now you know that that stain down there that is an ABO type O plus this other marker exists in about 25 percent of the population or about one out of every four people, rather than one out of every two. With each additional marker you add you keep multiplying that percentage and the number of possible people that could have left the stain gets smaller and smaller.

80 MR. GOLDBERG:

So if you had a third marker in your hypothetical that was also fifty percent, you would multiply 25 times 50 for 12 and a half?

81 MR. BLASIER:

Your Honor, I'm going to object and move to strike that last answer as being lack of foundation and I think we need to approach on this.

82 THE COURT:

Overruled.

83 MR. MATHESON:

Yes, that's correct. With each additional marker, if it was half, you would keep cutting the number in half. It would go to one in four to one in eight to one in sixteen and so on.

84 MR. GOLDBERG:

And is this use of the product rule in calculating the percentage of the population that has a given set of genetic markers one that is accepted in the forensic science community?

85 MR. MATHESON:

Yes, it is.

86 MR. GOLDBERG:

For how long has this been used?

87 THE COURT:

Which?

88 MR. GOLDBERG:

If you know the product rule in terms of applying it in this context with ABO systems and the other genetic markers?

89 MR. BLASIER:

Objection, vague to "Other genetic markers."

90 THE COURT:

Sustained.

91 MR. GOLDBERG:

Well, the ABO system plus the other enzyme system that you typed?

92 MR. BLASIER:

Vague.

93 THE COURT:

Vague. What system?

94 MR. GOLDBERG:

Well, you said that there are about eight or so enzyme systems that you type?

95 MR. MATHESON:

That we have the capability of typing in our laboratory, yes.

96 MR. GOLDBERG:

And is that pretty standard throughout the forensic community, that those are the systems that are used?

97 MR. MATHESON:

With some slight variation, but yes.

98 MR. GOLDBERG:

With respect to the systems that are used in your laboratory, how long, if you know, has the product rule been used to calculate the frequencies of those systems together with ABO?

99 MR. MATHESON:

Well, it has been used in our laboratory since I started, which was in 1978, and I believe the markers have been available, they have been used with each new one as it is developed.

100 MR. GOLDBERG:

Okay. Now, in terms of the conventional serology, and the electrophoresis tests that you have been discussing this morning, is there a problem with cross-contamination between the sample as you are doing the test?

101 MR. MATHESON:

I'm sorry, would you repeat the question.

102 MR. GOLDBERG:

Is there a problem with cross-contamination as you are testing these items?

103 MR. MATHESON:

If I understand what you are saying, I mean you always want to be careful that you don't allow one item to come in contact with another one so that you have the potential of transferring information between the two.

104 MR. GOLDBERG:

How sensitive is this particular test?

105 MR. MATHESON:

These--

106 MR. BLASIER:

Objection without some definition.

107 THE COURT:

Sustained.

108 MR. GOLDBERG:

How much of a sample do you need in order to be able to test an item of evidence using electrophoresis?

109 MR. MATHESON:

For the systems that we use, we need a sample that has, you know, some color to it, you know, towards a pale to dark red. Approximately a quarter inch long thread size is about the sample you need to get a good result.

110 MR. GOLDBERG:

If we were to define contamination as being introducing something onto a piece of biological evidence that was to cause the evidence to be mistyped, what would you need to do in order to contaminate biological evidence using that definition?

111 MR. MATHESON:

Well, in the area of the conventional type of typing we are talking about, you don't get results with--with samples that you can't see. It would have to be sufficient quantity that you are visibly seeing that you are transferring sample from one to the other.

112 MR. GOLDBERG:

So it would be something that you would visually see?

113 MR. MATHESON:

Yes.

114 MR. GOLDBERG:

And to your knowledge has there ever been a problem of contamination as I have defined it, inside of your laboratory in the serology section?

115 MR. MATHESON:

A problem as far as contamination in the conventional systems?

116 MR. GOLDBERG:

Yes.

117 MR. MATHESON:

Not to my knowledge, no.

118 MR. GOLDBERG:

Okay. And in the area of PCR testing, do you use kits that are manufactured by an outside firm?

119 MR. MATHESON:

Yes, we do.

120 MR. GOLDBERG:

Who does that come from?

121 MR. MATHESON:

The company has changed names a couple times. It was originally Cetus. I believe it is Roche Biochemicals now.

122 MR. GOLDBERG:

And with respect to those kits, to your knowledge, has there ever been any defect in the kits that you were supplied?

123 MR. MATHESON:

Well, I was made aware of a time in our laboratory where we were getting results showing up in our controls and other areas in the process that was eventually, we believe, traced back to a particular lot of kits.

124 MR. GOLDBERG:

Was that prior to June 14th of last year?

125 MR. MATHESON:

Yes, it was.

126 MR. GOLDBERG:

Can you give us an estimation of how much prior?

127 MR. MATHESON:

At least a couple months. I'm not exactly sure of the date.

128 MR. GOLDBERG:

And what was this problem?

129 MR. MATHESON:

Well, we were showing a type within that system was typeable or becoming apparent in our controls in areas where we were not expecting to see any result at all.

130 MR. GOLDBERG:

What do you mean it was becoming apparent in the controls?

131 MR. MATHESON:

Well, there are controls built into the system that allow you to check whether or not the presence of contamination. Contamination is a fact of life when it comes to forensic samples, so you always have control built in, both the controls that are picked up at the scene, plus controls that are introduced at different stages of the testing that should come out blank when you are all done, should not yield a result. And if a result is obtained during--you know in some of these controls, it shows that there is some sort of contamination occurring.

132 MR. GOLDBERG:

And did the controls in fact work for that purpose in this incident?

133 MR. MATHESON:

Yes, they did.

134 MR. GOLDBERG:

Now, was this an incident that you were personally involved in or had personal involvement with?

135 MR. MATHESON:

No.

136 MR. GOLDBERG:

Did you ever read any documentation, around the time that it occurred, pertaining to the incident?

137 MR. MATHESON:

No, I did not.

138 MR. GOLDBERG:

And how was it resolved?

139 MR. MATHESON:

I was advised by the people that were doing the tests that upon receiving a new lot kit from the company we were no longer seeing that type showing up in our controls.

140 MR. GOLDBERG:

When you say "A lot," what are you talking about?

141 MR. MATHESON:

Well, when things are produced or manufactured they put a lot number on it so that you can track. I would assume they came from the same batch of chemicals or whatever in the factory, but it is an assigned lot number to a sequence of reagents or kits.

142 MR. GOLDBERG:

Okay. Now, going back to a conventional testing for a moment, in the area of conventional testing does the laboratory take proficiency tests?

143 MR. MATHESON:

Yes.

144 MR. GOLDBERG:

And what are those?

145 MR. MATHESON:

Well, we subscribe to a couple of different outside companies that supply us with unknown samples. One of them is collaborative testing service and the other is cap or the College of American Pathologists. They send us case-like samples. We don't know the results of them. And as supervisor I would receive these items and either, if there was sufficient sample, divide them up between a number of the analysts within the laboratory, or if it was a small sample, assign to it one particular analyst, and they would test them, we would then submit our results to whatever company it happened to be, and then I get the results back from them at a later time.

146 MR. GOLDBERG:

And do you also take proficiency tests in the area of PCR testing in your laboratory?

147 MR. MATHESON:

Yes.

148 MR. GOLDBERG:

And how is that done?

149 MR. MATHESON:

The similar process. As a matter of fact, the--both CAP and CTS are gearing them more now toward the DNA process than conventional.

150 MR. GOLDBERG:

And have those proficiency tests been passed?

151 MR. MATHESON:

Yes.

152 MR. GOLDBERG:

Now, we were talking a little bit about the substrate controls and the use of the controls yesterday. When you are doing your conventional testing, do you use those controls in any way?

153 MR. MATHESON:

Yes, I do, for part of the testing.

154 MR. GOLDBERG:

For what part do you use them?

155 MR. MATHESON:

I use them during the course of determining whether or not a sample is human and in the ABO testing.

156 MR. GOLDBERG:

When you use a substrate control, when you use substrate controls in this case, did you use the entire cloth square or a portion of it?

157 MR. MATHESON:

Just a portion.

158 MR. GOLDBERG:

What do you do with it in order to take a portion?

159 MR. MATHESON:

I would--I open up the bindle that contains it and I would make a cutting from it that is appropriate size for the tests that I want to run. I may not do a cutting. Sometimes I will actually take tweezers or forceps and tease out a couple of the threads or fibers that are present.

160 MR. GOLDBERG:

And why is that used in the ABO system?

161 MR. MATHESON:

Because it is known that there are things out there besides ABO substances that will give activity or results that can mimic or look like ABO. Certain types of cloth can tend to give you what is called a false positive for an ABO antigen which is one of the things we look at when we are typing for the ABO system and you want to know if the surface with your stain on it is going to have this type of activity present.

162 MR. GOLDBERG:

Was the laboratory using substrate controls prior to the use of PCR technology?

163 MR. MATHESON:

Yes.

164 MR. GOLDBERG:

And was it because of the ABO system for the reasons that you just described that you did?

165 MR. MATHESON:

Yes, that's correct.

166 MR. GOLDBERG:

What about for the other genetic markers that you are typing? Do you use the substrate control for that?

167 MR. MATHESON:

No, I do not.

168 MR. GOLDBERG:

Why do you not use them for those?

169 MR. MATHESON:

Well, as opposed to the ABO system where I mentioned there are things out there that can mimic the same type of activity, that is not true for the enzyme systems that we use.

170 MR. GOLDBERG:

What about the idea of testing them for the purposes of determining of whether there was any type of contaminant on the substrate control? Why won't you do that when you are testing?

171 MR. MATHESON:

Well, I do use it for the human test, and if that comes up negative, there is no biological material present that would give me a result.

172 MR. GOLDBERG:

Would you expect to get any result on electrophoresis, if you saw a substrate control that had no visible blood on it?

173 MR. MATHESON:

Of we are talking about a blood stain, no, I would not.

174 MR. GOLDBERG:

Now, in June and September of last year did you do certain testing on some of the items bearing the DR number of this case?

175 MR. MATHESON:

Yes, I did.

176 MR. GOLDBERG:

And did you generate reports related to that testing?

177 MR. MATHESON:

Yes.

178 MR. GOLDBERG:

I this time I would like to mark what's called the "Serology results" chart as People's next in order.

179 THE COURT:

That will be--

180 MR. GOLDBERG:

216.

181 THE COURT:

216.

182 MR. GOLDBERG:

Sir, directing your attention to People's for identification, have you seen this chart before?

183 MR. MATHESON:

Yes, I have.

184 THE COURT:

All right. Mr. Goldberg, didn't we mark this earlier as 202?

185 MR. GOLDBERG:

The chart?

186 THE COURT:

Miss Martinez confirms that.

187 MR. GOLDBERG:

Yes, you do.

188 THE COURT:

All right. People's 2 02. Mr. Goldberg.

189 MR. GOLDBERG:

Thank you.

190 MR. GOLDBERG:

Sir, showing you People's 202 for identification, does that summarize information that was contained on reports that you generated in connection with your testing in this case?

191 MR. MATHESON:

It summarizes information from the reports, plus some additional information from some of the notes.

192 MR. GOLDBERG:

All right. Now, starting first with the notes, what kind of notes do you generate when you are testing items contemporaneously with the testing?

193 MR. MATHESON:

Well, there is--while the testing is going on what is prepared is a serology case summary sheet which will eventually have a summary of all the results on each of the items. While I'm doing this I'm referring to some notes I have of my analysis from June of 1994, just so I can make sure I can remember all the different forms. So I described this as a serology case summary sheet. There is also what has been previously described "Serology item description notes." Those are the notes where we give a little bit more detailed description of the actual item. And then there are what are called electrophoresis work sheets that are created during the electrophoresis process. Each plate that you saw earlier will have a sheet that goes along with it to identify the different samples and where they are located on the gel. There may also be just note pages, blank pages. Sometimes we will write on the back of some these for some additional information.

194 MR. GOLDBERG:

Are the notations, the notes that you just referred to, ones that have been labeled with "L" numbers and provided to both sides in discovery?

195 MR. MATHESON:

Yes, that's correct.

196 MR. GOLDBERG:

Umm, now, which are the reports that are done at the time of the test? Which of the two types of reports that are done contemporaneously with the test?

197 MR. MATHESON:

Well, the type that is done contemporaneously with the test, the electrophoresis work sheet which would go along with each of the electrophoresis runs I described. There is also I mentioned that sometimes we will take notes on the back of a page. In the ABO blood typing test we don't have necessarily a form where that is recorded. A lot of times we just write the raw data on the back of one of the other pages and that is done while you are actually doing the analysis.

198 MR. GOLDBERG:

And what type of information or where did the information come from that was used to compile this chart? Was it just the reports, the analyzed evidence reports or also the electrophoresis work sheets?

199 MR. MATHESON:

I believe information that went onto this report came from my reports--or were put on this--came from my reports--a combination of that, the case summary sheet and the electrophoresis work sheets.

200 MR. GOLDBERG:

Now, does this particular chart contain test results of testing that you did between June the 27th and 29th on the reference samples, 17, 59 and 60 and also item 49?

201 MR. MATHESON:

Yes, it does.

202 MR. GOLDBERG:

And who actually did that testing physically?

203 MR. MATHESON:

Well, it depends on which part you are talking about. I did some and then I observed some placement and some of the actual hands-on work on the electrophoresis was done on Mr. Yamauchi.

204 MR. GOLDBERG:

When you say that the electrophoresis was done by Mr. Yamauchi, what did he do? Was it in your presence?

205 MR. MATHESON:

Most of it was; not all of it.

206 MR. GOLDBERG:

What did you see him doing?

207 MR. MATHESON:

Well, one of the most important parts of that test, as far as sample continuity, is recorded on the electrophoresis sheet which sample goes in which lane and then making sure that the sample you are saying is on this sheet is actually in that lane. I sat alongside of him while we sampled, you know, opened up, in the case of, say, item no. 49, opened up the bindle, cut a small portion from the swatch, it was then placed into a numbered well which corresponded with a number on the electrophoresis sheet. And I watched him then transfer that into the gel along with the exemplar samples and the known standard samples that were included.

208 MR. GOLDBERG:

So he did the physical manipulations in terms of loading the gel?

209 MR. MATHESON:

When it came to the electrophoresis work, yes.

210 MR. GOLDBERG:

And that was in your presence?

211 MR. MATHESON:

Yes, it was.

212 MR. GOLDBERG:

And then what happened after the gel had been run and the results were ready to be read?

213 MR. MATHESON:

At that point he took photographs of them. When I was available I co-read them with him and we determined what types were present on the plate.

214 MR. GOLDBERG:

Now, sir, do you recall testifying about the tests when you testified at the preliminary hearing in this case?

215 MR. MATHESON:

Yes, I do.

216 MR. GOLDBERG:

Counsel, directing your attention to page 4 of the preliminary hearing on July the 8th, 1994. I would like to read between lines 2 and lines 23.

217 MR. BLASIER:

Page 4, what line?

218 MR. GOLDBERG:

Between 2 and 23.

219 (Brief pause.)
220 MR. BLASIER:

Objection, hearsay.

221 THE COURT:

Sustained.

222 MR. GOLDBERG:

Does the Court have a copy?

223 THE COURT:

Yes, I do, page 4. Sustained.

224 MR. GOLDBERG:

Prior inconsistent statement. Well, hold on for a second.

225 (Discussion held off the record between the Deputy District Attorneys.)
226 THE COURT:

You are saying 1235 is an exception?

227 (Nods head up and down.)
228 THE COURT:

Is that yes?

229 MR. GOLDBERG:

Yes.

230 THE COURT:

Proceed.

231 (Brief pause.)
232 MR. GOLDBERG:

Sir, at the preliminary hearing did you testify as follows to the following questions? "Question: I think where we left off yesterday I think you indicated that you tested item 49 which was the blood drop from the trail left at 875 South Bundy shown in the close-up of photograph e and shown in the perspective in photograph D. "Do you recall saying that? "Answer: That's correct. "Question: And you tested--and you tested that initially to determine if it was human origin? "Answer: Yes. "Question: And with respect to the blood samples that were retrieved from the Defendant and from Ronald Goldman and Nicole Brown Simpson, with respect to those samples, did you test them also? "Answer: Yes, I did. "Question: What test did you perform on those? "Answer: On those I performed the ABO blood typing test, the group 1 enzyme electrophoresis test and the PGM subtype electrophoresis test. "Question: And did you also subject the blood drop from the trail, item 49, to those same tests? "Answer: Yes, I did."

233 MR. GOLDBERG:

Do you recall that testimony?

234 MR. MATHESON:

Yes, I do.

235 MR. GOLDBERG:

Now, sir, when you answered those questions did you specify that the physical loading onto the gel was actually done by Mr. Yamauchi in your presence?

236 MR. MATHESON:

No, I did not.

237 MR. GOLDBERG:

And why not?

238 MR. MATHESON:

I didn't think it was necessary.

KEY QUOTE
239 MR. GOLDBERG:

Were the two of you working together as a team in doing this?

240 MR. MATHESON:

Yes, we were.

241 MR. GOLDBERG:

And did you observe all of the critical parts in the analysis?

242 MR. MATHESON:

Yes, I did.

243 MR. GOLDBERG:

And did you feel--were you trying to mislead anyone or leave Mr. Yamauchi out in answering those questions in that way?

244 MR. MATHESON:

No, not at all.

245 MR. GOLDBERG:

Is it common in your laboratory for analysts to work together in the laboratory using a team approach such as that? Does that happen?

246 MR. MATHESON:

It happens, yes.

247 MR. GOLDBERG:

And where you observe the critical aspects of what the other analyst did?

248 MR. MATHESON:

Yes.

249 MR. GOLDBERG:

And is that what happened with respect to the typing on 17, 59, 60 and 49?

250 MR. MATHESON:

Yes, it is.

251 MR. GOLDBERG:

Now, Mr. Matheson, did you also generate an analyzed evidence report describing the testing that you did and Mr. Yamauchi did on these items?

252 MR. MATHESON:

Yes, I did.

253 MR. GOLDBERG:

And I would like to mark that as People's next in order. It is L-7778 for counsel's benefit.

254 THE COURT:

Mrs. Robertson, next in order, People's--

255 THE CLERK:

216.

256 THE COURT:

216.

257 (Peo's 216 for id = analyzed evid rpt)
258 MR. GOLDBERG:

It is entitled "Analyzed evidence report." The date the analysis completed is 6/28.

259 (Brief pause.)
260 THE COURT:

All right. Proceed.

261 MR. GOLDBERG:

We are going to have to lower the serology results chart a little bit in order to put this on the elmo.

262 (Brief pause.)
263 THE COURT:

It may be necessary to remove it entirely.

264 MR. GOLDBERG:

To what?

265 THE COURT:

Remove it entirely, but let's try that. Let's try that.

266 (Brief pause.)
267 MR. GOLDBERG:

Sir, do you recognize the document that we just put on the elmo, People's 216 for identification?

268 MR. MATHESON:

Yes, I do.

269 MR. GOLDBERG:

What is that?

270 MR. MATHESON:

That is a copy of my analyzed evidence report.

271 MR. GOLDBERG:

And was this analyzed evidence report generated--when was this generated in relationship to the testimony at the preliminary hearing that we just read?

272 MR. MATHESON:

Well, it was generated immediately following testing prior to the preliminary hearing.

273 MR. GOLDBERG:

Okay. Can we see the full--first full paragraph where it starts with "ABO testing was performed."

274 MR. GOLDBERG:

Mr. Matheson, did you write this form?

275 MR. MATHESON:

Yes, I did.

276 MR. GOLDBERG:

And could you just read for us what you wrote in the first full paragraph saying--that starts "All ABO typing."

277 MR. MATHESON:

Well, the first paragraph is just that one line that says, and I am reading from a copy of the report myself rather than off one of the monitors: "All ABO typing was performed exclusively by Matheson, B-8927."

278 MR. GOLDBERG:

And what was the next paragraph starting with "Criminalist Yamauchi"?

279 MR. MATHESON:

The next paragraph starts with: "Enzyme typing for ESD, PGM, PGM subtype and GLO were performed by criminalist Yamauchi, G-880. All evidence handling, including original sampling and transfers to the gel, were witnessed by Matheson. All results were confirmed in person or by photographs by Matheson."

280 MR. GOLDBERG:

So did you--why did you write these two paragraphs to describe what you did and what Mr. Yamauchi did?

281 MR. MATHESON:

To be accurate as far as exactly who performed what tests for the report.

282 MR. GOLDBERG:

Okay. And you wrote this paragraph out prior to testifying at the preliminary hearing where you said that you did the electrophoresis tests?

283 MR. MATHESON:

Yes, I did.

284 MR. GOLDBERG:

All right. Thank you. Now, we have been using the term "Reference samples." What does that mean?

285 MR. MATHESON:

The way I use it is it refers to the known blood sample or blood samples of a known source related to a case.

286 MR. GOLDBERG:

And our serology results chart, how are those designated?

287 MR. MATHESON:

The reference samples that are designated on the chart are first indicated by the item number and then in parentheses by the person that they were taken from.

288 MR. GOLDBERG:

And the little blood drops would designate what?

289 MR. MATHESON:

As far as the icons go, the blood drops reference a stain or evidence material.

290 MR. GOLDBERG:

And when you do these tests are you comparing the results from the reference samples to the results that you get on the unknowns that are designated with these little blood drops?

291 MR. MATHESON:

Yes.

292 MR. GOLDBERG:

Now, in September of 1994 did you also do another series of testing on items that are represented in the People's serology results chart?

293 MR. MATHESON:

Yes. I started some testing in September.

294 MR. GOLDBERG:

And on September 11th what item numbers that are on the results chart did you test, if any?

295 MR. MATHESON:

Okay. On September 11th?

296 MR. GOLDBERG:

Yeah.

297 MR. MATHESON:

Was when I started working on item no. 42, item no. 44, 50--item no. 54, item no. 84-A and B and item no. 85-A and b.

298 MR. GOLDBERG:

And on September the 20th did you do some testing on items that are contained on the serology results chart?

299 MR. MATHESON:

Okay. I'm going to be referring to my notes. I received some additional items on September 18th. As far as doing the analysis, yes, there was some analysis done on September 20.

300 MR. GOLDBERG:

Which items?

301 MR. MATHESON:

That would be on item no. 13 and item no. 37.

302 MR. GOLDBERG:

When you say 13, on the chart we have 13-A. Is that the little cutting that you testified to earlier this morning?

303 MR. MATHESON:

Yes.

304 MR. GOLDBERG:

That you took off the--one of the socks, item 13?

305 MR. MATHESON:

That's correct.

306 MR. GOLDBERG:

And did you also do some testing on September the 27th on items that are contained on the serology results chart?

307 MR. MATHESON:

Again referring to electrophoresis work sheet, I did run some samples on that date, yes.

308 MR. GOLDBERG:

Which ones?

309 MR. MATHESON:

That would be item no. 57 and item no. 78.

310 MR. GOLDBERG:

And where were those items stored during the testing that you did in September?

311 MR. MATHESON:

They were in the freezer in the serology unit.

312 MR. GOLDBERG:

Now, with regard to these various items that are on the serology results chart, when you were looking at the Los Angeles Police Department evidence--evidence disposition summary boards, People's 177, did it contain the packaging of these various items represented on the photographs on those exhibits?

313 MR. MATHESON:

Yes, it did.

314 MR. GOLDBERG:

And when you were doing the testing was the--were the items coming out of the original packaging or the transmittal packaging that was used later on when it was sent out?

315 MR. MATHESON:

I believe out of the original.

316 MR. GOLDBERG:

Okay. But in each case did you look at the item number and DR number prior to the test to confirm what you were testing?

317 MR. MATHESON:

Yes.

318 MR. GOLDBERG:

Now, going back to the serology results chart, there is a column that says "ABO." What does that refer to?

319 MR. MATHESON:

That refers to the ABO blood typing system that I have described previously.

320 MR. GOLDBERG:

And what does "ESD" mean right next to ABO?

321 MR. MATHESON:

ESD are the initials for one of the enzymes that we analyzed that I previously described.

322 MR. GOLDBERG:

And what about PGM subtype?

323 MR. MATHESON:

The same thing. It is an enzyme that can be broken down into types.

324 MR. GOLDBERG:

And EAP, what does that mean?

325 MR. MATHESON:

EAP are also initials standing for another enzyme that we use.

326 MR. GOLDBERG:

What is in the "Consistent with" column?

327 MR. MATHESON:

Consistent with are a list of names that are placed there when a comparison could be made between the evidence samples and the exemplar or reference samples.

328 MR. GOLDBERG:

And what about the "Frequency"? What does that represent?

329 MR. MATHESON:

Frequency gives an indication of how common that combination of types occurs in general population.

330 MR. GOLDBERG:

Now, on this particular chart there is a number of items that are in blue that say "Inc." What does that mean?

331 MR. MATHESON:

"Inc" stands for inconclusive.

332 MR. GOLDBERG:

How is that reported when you actually write out an analyzed evidence report?

333 MR. MATHESON:

Any result that is determined to be inconclusive at the time that it is run is written strictly as either inc or inconclusive on the report with no indication of the type given.

334 MR. GOLDBERG:

So it wouldn't say on your analyzed evidence report, for instance, for item no. 42, "Inconclusive b"?

335 MR. MATHESON:

No, definitely not.

336 MR. GOLDBERG:

And where does that information come from?

337 MR. MATHESON:

It comes from a combination of the case summary notes and the original electrophoresis work sheet.

338 MR. GOLDBERG:

Well, why don't you write exactly word for word what is on the electrophoresis work sheet and the case summary notes onto the analyzed evidence report? Why don't they match a hundred percent?

339 MR. MATHESON:

Well, the electrophoresis work sheet is just that, it is a work sheet that is being used while the test is being run. You are recording the conditions of the test and you are recording all observations and in--not interpretations, but observations that are made on the plate. We even include guesses at that point. Our--and if it is a guess, it is marked as inconclusive. That information then is transferred over to the summary sheet intact, kind of summarizing the information on the work sheet. If it is inconclusive, it is marked as "Inc" and the potential or possible guess of the type is placed in that column. However, when a report is written, it just reflects "Inconclusive."

340 MR. GOLDBERG:

So is an inconclusive statement, if it says "Inconclusive B," does that mean that it could be wrong?

341 MR. MATHESON:

It is possible.

342 MR. GOLDBERG:

And is that why you say inconclusive?

343 MR. MATHESON:

Well, inconclusive means just that, it is not a conclusive decision or conclusive result as to what the analysis showed.

KEY QUOTE
344 MR. GOLDBERG:

And does that mean that as a forensic scientist when you say something is inconclusive, let's say on your work sheet, you said it was inconclusive B, would you be willing to report in Court that it was in fact a b?

345 MR. MATHESON:

No, I would not.

346 MR. GOLDBERG:

And why is that?

347 MR. MATHESON:

Again, it is not a conclusive result. I don't want to put something down on my report or present to Court unless I'm sure as to what the result is.

348 MR. GOLDBERG:

So what is the point then of writing "Inconclusive B," for example, on the electrophoresis work sheet if you don't put it on the analyzed evidence report and you are not willing to testify in Court that it was in fact a b?

349 MR. MATHESON:

Well, because it is information. First off, the work sheet, like I described, it is things you are recording as you are reading it. I mentioned earlier that sometimes the band, they get darker with time and what may start out as a type with a question mark, or an inconclusive, over time may become a conclusive reading as it gets darker and more easy to read. There are times where you will record something as a potential inconclusive or with a question mark and that is the way it stays; it just never gets any better.

350 MR. GOLDBERG:

What kind of information can those provide, though?

351 MR. MATHESON:

Well, potentially it can show--give you an idea what might not be there but it is still not a conclusive result.

352 MR. GOLDBERG:

Okay. Now, we were talking about degradation yesterday and whether or not a degraded sample could turn from one blood type into another. Do you recall that conversation?

353 MR. MATHESON:

Yes, I do.

354 MR. GOLDBERG:

And you said that that is not a problem except with respect to one of the genetic marker systems. What did you mean by that?

355 MR. MATHESON:

Well, the majority of the markers that we look at, like I mentioned, as they degrade they just get weaker and weaker and you can't determine a type. It doesn't change into another type. The most notable exception to that is in the system that goes by the initials of EAP. EAP is the type of system that I mentioned before that there were situations where it was the location of the band or the number of bands that tells you what type it is and there are other ones that deal with intensity of the bands. EAP is one of those types of systems. You look at the intensities and take that into consideration when you are determining what the type is. So in the case of EAP, it is known that a degradation route occurs where the bands become less and less intense and can eventually be mistyped.

356 MR. GOLDBERG:

Now, with respect to the PGM subtype, do you have those same issues in PGM subtype that you have in EAP?

357 MR. MATHESON:

Not when it comes to evidentiary samples. It has been shown that liquid blood stored for a long period of time, you can start slowly losing the minus bands. You will notice under the PGM subtype there is a plus and a minus indication. It is possible to eventually see the minus bloods degrade but that does not occur in dried samples.

358 MR. GOLDBERG:

So in dried samples such as a stain, what happens in the PGM subtype system when you get degradation?

359 MR. MATHESON:

The bands just become weaker and weaker to the point where when you develop it on the gel you just don't see anything.

360 MR. GOLDBERG:

Can you have a situation in the PGM subtype where the bands have degraded so that you can see something there but it is an inconclusive?

361 MR. MATHESON:

Oh, sure. That is another use of inconclusive, is that we know something is occurring where you can see that there is something there. Another indication we have goes by the initials of NA or no activity. If you see kind of a hazy appearance in the band area, you can't say no activity because something is going on, so it would be recorded as inconclusive.

362 MR. GOLDBERG:

So let's just take one example, item 13a that has the PGM subtype of 1 plus. Now, this was--is this a result that you classify as being inconclusive or is this a final result?

363 MR. MATHESON:

That is a final result.

364 MR. GOLDBERG:

So what does that mean, as opposed to an inconclusive result in this particular case?

365 MR. MATHESON:

It means that the blood stain that was present on that item is a PGM subtype 1 plus.

366 MR. GOLDBERG:

Now, could it have been something else and degraded into a 1 plus?

367 MR. MATHESON:

Not in my experience and knowledge, no.

KEY QUOTE
368 MR. GOLDBERG:

Okay.

369 (Discussion held off the record between the Deputy District Attorneys.)
370 MR. GOLDBERG:

And in this particular case the 1 plus would be consistent with whom?

371 MR. MATHESON:

Well, of the three parties that are on this chart, it is--can be--is consistent with the type that we found for item no. 59, Nicole Brown, and is inconsistent or definitely could not have come from the item no. 17 or in 60, Mr. Goldman.

372 MR. GOLDBERG:

Now, getting back to this issue that we were talking about on degradation, what about the ABO--what about the ESD results? Can degradation cause those results to change from one pattern to another?

373 MR. MATHESON:

No.

374 MR. GOLDBERG:

And what about ABO?

375 MR. MATHESON:

Not in ABO either, you won't get a change of the type.

376 MR. GOLDBERG:

So you have the four systems that we have here. Is EAP the only system that has this problem that you have been using where the degradation can make it appear to be something other than what it really was?

377 MR. MATHESON:

That's correct.

378 MR. GOLDBERG:

Now, Mr. Matheson, is this phenomena that exists within the EAP system, but not the others, one that is recognized in the forensic science literature?

379 MR. MATHESON:

Yes, it is.

380 MR. GOLDBERG:

And have you read articles that discuss the special issues that are inherent in the EAP system?

381 MR. MATHESON:

Yes, I have.

382 (Discussion held off the record between the Deputy District Attorneys.)
383 MR. GOLDBERG:

Did you read a chart, Mr. Matheson, that was by Dr. Grunbaum and Zajac entitled "Problems of reliability in the phenotyping of a erythrocyte acid phosphatase and bloodstains."

384 MR. MATHESON:

Yes, I have.

385 MR. GOLDBERG:

And did you consider that as part of this forensic science literature that we have been discussing that deals with the issue with EAP?

386 THE COURT:

All right. Mr. Goldberg, would you spell those items for the Court reporter.

387 MR. GOLDBERG:

Sure.

388 THE COURT:

All right.

389 MR. GOLDBERG:

Grunbaum is G-R-U-N-B-A-U-M and Zajac is Z-A-J-A-C. The article is "Problems of Reliability of Phenotyping," P-H-E-N-O-T-Y-P-I-N-G, "Of Erythrocyte," E-R-Y-T-H-R-O-C-Y-T-E, "Acid Phosphatase," P-H-O-S-P-H-A-T-A-S-E.

390 THE COURT:

Thank you.

391 MR. GOLDBERG:

Thank you.

392 MR. GOLDBERG:

By the way, it is erythrocyte acid phosphatase what we are designating with the initials EAP?

393 MR. MATHESON:

Yes, it is.

394 MR. GOLDBERG:

And in our preparations in our sessions where we discussed the case prior to your testimony, did you teach me at some length how to pronounce that term?

395 MR. MATHESON:

Yes.

396 MR. GOLDBERG:

How did I do?

397 MR. BLASIER:

Objection, irrelevant.

398 THE COURT:

Sustained.

399 MR. GOLDBERG:

Okay.

400 MR. GOLDBERG:

Now, with respect to the article that we just talked about--

401 (Discussion held off the record between Deputy District Attorney and Defense counsel.)
402 MR. GOLDBERG:

May I approach the witness?

403 THE COURT:

Please.

404 MR. GOLDBERG:

Sir, I'm showing you an article that we just read the title of. Is this one of the articles that you looked at?

405 MR. MATHESON:

Yes, it is.

406 MR. GOLDBERG:

And on page 617 of that article does Dr. Grunbaum discuss some of the issues that you have been explaining to us this morning about the EAP system?

407 MR. MATHESON:

Yes.

408 MR. GOLDBERG:

And can you read for us the first full paragraph of what Dr. Grunbaum says.

409 MR. MATHESON:

"Although only a limited number of samples were used in this initial experiment, the results shown in table 1 clearly indicate that there can be a definite problem with the EAP phenotyping no matter which electrophoretic supporting medium is used."

410 MR. GOLDBERG:

What does that mean?

411 MR. MATHESON:

Well, the electrophoretic supporting medium is in the case that we showed, the example agarose, there are just different types of terms that it can be run. The paragraph just indicates that there can be problems with this--using this system.

412 MR. GOLDBERG:

And can you read the second full paragraph.

413 MR. MATHESON:

"Unlike other enzyme systems, EAP phenotyping depends not only on a pattern of relative distribution of bands but also on the relative intensities of the bands. When blood is aged, the individual isoenzymes" those are the bands in it, "Tend to degrade at different rates, further, exacerbating the difficulties of true phenotype identification."

414 MR. GOLDBERG:

I think you have explained this already in your testimony in different terms; is that correct?

415 MR. MATHESON:

Yes, basically.

416 MR. GOLDBERG:

Okay. And with respect to the last full paragraph under "Summary," can you read that for us?

417 MR. MATHESON:

I'm sorry, are we talking about the underlying part or the paragraph itself?

418 MR. GOLDBERG:

The paragraph.

419 MR. MATHESON:

"Erythrocyte acid phosphatase is a useful system for the crime laboratory for both fresh and degraded blood and bloodstains, provided the inherent problems of phenotyping this particular enzyme system are recognized. Because of the great number of variables affecting this enzyme system in vitro, phenotyping should not be attempted until the complete history of origin and handling of the sample is known."

420 MR. GOLDBERG:

Now, with respect to the last point about not typing erythrocyte acid phosphatase unless the complete history and origin of the sample is known, what does that refer to?

421 MR. MATHESON:

Well, his reference there I believe is suggesting that you should not be doing this until you know exactly what the history of it is, which means where it was deposited, potentially the length of time, the conditions it was under, as opposed somebody just walking into a laboratory with a blood stain.

422 MR. BLASIER:

Your Honor, I object and move to strike. No foundation that he knows what that author meant.

423 THE COURT:

Sustained.

424 MR. GOLDBERG:

Sir, within the forensic science community is there a--are there analysts that believe that you should know the complete history and origin of a sample before starting EAP testing--before making an EAP conclusion?

425 MR. BLASIER:

Objection, no foundation.

426 THE COURT:

Sustained.

427 (Discussion held off the record between the Deputy District Attorneys.)
428 MR. GOLDBERG:

What did you understand that to mean in terms of your reading of the article and your interpretation of the article?

429 MR. MATHESON:

Well, my reading of that, I understand as being suggested that it is important to understand the history behind a sample, what conditions it was collected and preserved under.

430 MR. GOLDBERG:

And where do you stand on that particular issue as to whether or not that is necessary?

431 MR. MATHESON:

Well, I kind of sit in the middle of it. There are differences of opinion of this and this has been an area of discussion when it comes to dealing with samples and serology in general, in that some people feel it is very important that the criminalist not be biased by any sort of outside information or receive a blood stain, you know, cold without anything and you just report the results that you find. There are also those that believe, as indicated in that article, that it is important to know the background, the story behind how the sample was deposited and taking all of that into account. I don't really believe in either extreme. I don't particularly like to work in the dark. That is very difficult to do. However, I also appreciate the fact that you do not want your opinion biased in anyway by any information that isn't directly related to the evidence.

432 MR. GOLDBERG:

Okay. Now, with respect to the EAP system you were talking about that in this system, that not only do you look at the bands but you also look at the intensity of the band; is that correct?

433 MR. MATHESON:

Yes, it is.

434 MR. GOLDBERG:

Does that distinguish it from PGM subtype?

435 MR. MATHESON:

Yes.

436 MR. GOLDBERG:

Why?

437 MR. MATHESON:

Well, in PGM subtyping it is the location of the band, where it appears on the gel in relation to your known standard, as opposed to how strong or how light the bands are.

438 MR. GOLDBERG:

So you are not looking at the intensity or brightness the band when you are talking about PGM subtype?

439 MR. MATHESON:

That's correct.

440 MR. GOLDBERG:

Given that you are looking at the intensity of the band on EAP as opposed to PGM subtype, is there some element of subjectivity in terms of making a call as to an EAP result?

441 MR. MATHESON:

Yes, there is.

442 MR. GOLDBERG:

What is that?

443 MR. MATHESON:

Well, not only do these systems differ in intensity versus band location, they are also developed differently. The PGM system is developed, you get a dark blue, almost black band that you look at under visible light. In the EAP system the band you are looking at, you have to look under ultraviolet light, and rather than being dark they are actually a light source, they are bright. And people's eyes see different things, as far as the intensity of what they are looking at. It is a very subjective call.

444 MR. GOLDBERG:

So you don't have that problem, though, with PGM--

445 MR. MATHESON:

No.

446 MR. GOLDBERG:

--subtype? What about with ABO or is this applicable to ABO?

447 MR. MATHESON:

There is no comparison to ABO on this.

448 MR. GOLDBERG:

Your Honor, I would like to mark as People's --

449 THE COURT:

217.

450 MR. GOLDBERG:

--217, another board that says "EAP phenotype board."

451 THE COURT:

All right. 217.

452 (Peo's 217 for id = posterboard)
453 MR. GOLDBERG:

Mr. Fairtlough, can you lower it down a little bit so perhaps we can also put some pictures on the elmo later on.

454 (Brief pause.)
455 MR. GOLDBERG:

Mr. Matheson, showing you People's 217 for identification, what is this exhibit?

456 MR. MATHESON:

What this exhibit shows is a block diagram or kind of a graphical representation of the six most common EAP phenotypes.

457 MR. GOLDBERG:

Now, maybe we could just take a look at the photograph on the evidence testing board again that shows the plates on the electrophoresis machine. While we are waiting to put that up, can you go through the six common phenotypes and just explain to us--well, first of all, I know you have already described this, but a phenotype is what again?

458 MR. MATHESON:

Well, it is the type that is observed on the gel. It is identified for the eventual reporting.

459 MR. GOLDBERG:

Okay. Can you tell us what the six common EAP phenotypes are?

460 MR. MATHESON:

They appear on the right-hand column there; type A, type B, type C, type BA, type CB and type ca.

461 MR. GOLDBERG:

And when you are testing a system using the EAP system, is it--does it fall under one of these six types generally?

462 MR. MATHESON:

Generally it does, yes.

463 MR. GOLDBERG:

All right.

464 MR. MATHESON:

If--

465 MR. GOLDBERG:

Now, if you can take a look at our evidence testing board, we have a photograph of items being loaded onto the gel. Can you just orient these two exhibits for us and tell us I mean how this would correlate?

466 MR. MATHESON:

Well, to put the two in relation to each other, if you were to take the electrophoresis plate that you see up there and rotate it ninety degrees to the left, we are just putting the sample in what we refer to as the origin--the origin, the place where the sample starts, and that would correspond in the EAP diagram to the line or the area that is marked with the word "Origin" right above it.

467 MR. GOLDBERG:

And then you were talking about how after the electrophoresis machine is hooked up, the sample begins to migrate across the gel and that it creates a banding pattern. Can you describe for us what that would look like using the EAP phenotype board?

468 MR. MATHESON:

Well, using this as an example, you would start at the origin--we have already mentioned lanes, and a lane would refer to an area where a sample is placed and then it moves. It moves along in roughly the same size and shape or configuration as where you originally put your sample. So in this particular example we have six lanes that are marked by the six different types. Your sample would be placed in the origin well, at the origin, a current would pass through it and the different portions of the enzyme would be moving along. And at some point you stop that and develop it and you see the bands and their location.

469 MR. GOLDBERG:

Now, you said that when you are looking at this plate you look not only at the placement of the band, but also intensity. Can you describe that for us using this diagram?

470 MR. MATHESON:

Well, the--it is a block diagram and it is not an actual photograph or something of a plate. It is just a graphical representation of it. We look at intensities in the system. We also look at locations, where the bands appear. It is a combination of the two. As you can see under the lane that is marked "A," the block diagram shows bands in different places than in the B. I also want to point out at this point that we show a block appearing on the far left of it in each of the lanes. This is just consistent with every type and is insignificant when it comes to determining what the type is of the sample. So you see that the location difference between the a and the B, however, also graphically demonstrated by this, is the fact that they are of different sizes and the sizes are an indication of the intensity. You will notice in the a that they are about equal size, they show about equal intensity or brightness. The B, the larger block band, would show up as significantly brighter than the smaller block band in the B column, and that is consistent throughout the rest of the items.

471 MR. GOLDBERG:

Your Honor, I'm sorry, I was so excited about this EAP block diagram I didn't see that we had run over.

Temperature

procedural

Key Quotes (4)

Gregory Matheson
All evidence handling, including original sampling and transfers to the gel, were witnessed by Matheson. All results were confirmed in person or by photographs by Matheson.
Matheson reads from his own pre-preliminary-hearing report (People's 216) that already disclosed Yamauchi's hands-on role, undermining any suggestion he was hiding it.
Gregory Matheson
Inconclusive means just that, it is not a conclusive decision or conclusive result as to what the analysis showed.
Key distinction for the jury: inconclusive work-sheet notations (e.g., 'Inc B') are never reported as actual types in court testimony.
Gregory Matheson
Not in my experience and knowledge, no.
Direct answer that a dried blood stain typed as PGM 1-plus could not have degraded into that result from a different type — shoring up the evidentiary value of item 13-A against defense degradation arguments.
Gregory Matheson
I didn't think it was necessary.
Matheson's candid admission that he omitted Yamauchi's role at the preliminary hearing — left for the defense to exploit on cross.

Evidence (5)

People's 215
Posterboard titled 'Evidence Testing Demonstration' — five-cell photo layout showing the serology lab door, lab interior, gel plate being loaded, electrophoresis cooling tank, and a running gel
introduced and used to walk jury through electrophoresis process step by step
People's 202
Serology results chart summarizing ABO, ESD, PGM subtype, EAP, and GLO typing results for all evidence items and reference samples, with 'Consistent with' and 'Frequency' columns
discussed in detail; used as primary reference for testimony about item-by-item serological findings
People's 216
Matheson's analyzed evidence report (L-7778), dated 6/28/94, explicitly attributing ABO typing to Matheson and enzyme typing to Yamauchi with Matheson witnessing
introduced to rebut any implication that Yamauchi's role was concealed
People's 177
LAPD evidence disposition summary boards showing original packaging of evidence items
referenced to confirm Matheson tested items from original packaging
Informal
Grunbaum and Zajac article, 'Problems of Reliability in the Phenotyping of Erythrocyte Acid Phosphatase in Bloodstains' — forensic science literature on EAP degradation
referenced to support Matheson's acknowledgment that EAP degradation is a recognized documented problem

Notable Exchanges (3)

Hank GoldbergGregory Matheson
Goldberg proactively surfaced the preliminary hearing testimony where Matheson said 'I' performed the electrophoresis without mentioning Yamauchi, then had Matheson read his own contemporaneous analyzed evidence report that already documented Yamauchi's role — framing the omission as an innocent shorthand rather than deception.
strategic
Hank GoldbergRobert BlasierLance A. Ito
Blasier objected to reading the preliminary hearing transcript as hearsay; Ito sustained; Goldberg invoked Evidence Code 1235 (prior inconsistent statement exception); Ito reversed and allowed it — a small procedural skirmish over using Matheson's own prior testimony.
procedural
Hank GoldbergGregory Matheson
Extended back-and-forth on degradation: Matheson explained that EAP is the only system where degradation can cause a mistype (band intensity shifts), while ABO, ESD, and PGM subtype simply go inconclusive or blank — a key defense-mitigation point the prosecution established on direct.
revealing

Credibility Attacks (1)

⚔ Gregory Matheson
prior inconsistent statement
Defense set up (for later cross) the discrepancy between Matheson's preliminary hearing testimony — where he said 'I' tested items 17, 49, 59, and 60 using electrophoresis — and the reality that Yamauchi physically loaded the gels. Goldberg defused it by having Matheson admit the omission, explain it as team shorthand, and read his own pre-hearing report that already disclosed the division of labor.

Objections

5 objections (3 sustained, 2 overruled)
Proceeding 5875 • 471 utterances • Prosecution witness
Criminal Trial
Department 103
⚖️ Start
📂 MAY 2, 1995 📄 Direct examination of Gregory
MAY 2, 1995 KRT DvH TD